Trimethobenzamide

Summary

Trimethobenzamide (CHEMBL1201256) is an approved small-molecule antiemetic (ATC R06AA10); indicated across 1 condition including allergic disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R06AA10
• Indications: 1 condition
• Clinical trials: 3
• Chemistry: 388.5 Da · C21H28N2O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201256
Name	Trimethobenzamide
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5577
ChEBI	CHEBI:27796
ATC	R06AA10
Molecular formula	C21H28N2O5
Molecular weight	388.5
InChIKey	FEZBIKUBAYAZIU-UHFFFAOYSA-N

SMILES: CN(C)CCOC1=CC=C(C=C1)CNC(=O)C2=CC(=C(C(=C2)OC)OC)OC

IUPAC name: N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4,5-trimethoxybenzamide

ChEBI definition: The amide obtained by formal condensation of 3,4,5-trihydroxybenzoic acid with 4-[2-(N,N-dimethylamino)ethoxy]benzylamine. It is used to prevent nausea and vomitting in humans.

Pharmacological roles (ChEBI): antiemetic.

Also known as: Ametik damla, SID11112414

Parent form; salt/anhydrous children: CHEMBL1200887

Patent coverage: 1,501 distinct patent families (6,347 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Prelamin-A/C, D(2) dopamine receptor, Acetylcholinesterase, Sodium-dependent noradrenaline transporter, D(3) dopamine receptor, Voltage-gated inwardly rectifying potassium channel KCNH2, Cytochrome P450 2C19.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 8 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	7.25	Potency	56.2	nM	CHEMBL_ACT_3638918
DRD3	6.15	AC50	710	nM	CHEMBL_ACT_25194895
DRD3	5.66	AC50	2200	nM	CHEMBL_ACT_25193894
ACHE	5.49	AC50	3220	nM	CHEMBL_ACT_25142931
CYP2C19	5.2	Potency	6310	nM	CHEMBL_ACT_4018328
DRD2	5.16	AC50	6900	nM	CHEMBL_ACT_25140707
KCNH2	5.15	AC50	7100	nM	CHEMBL_ACT_25118384

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
allergic disease	2	MONDO:0005271	MONDO:0005271

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE1	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01770145	PHASE4	COMPLETED	Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
NCT02262767	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects
NCT02373072	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson’s Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).